Background. Universal pneumococcal vaccination (UPV) in Argentina began in January 2012 using a 2 + 1 schedule using PCV13; vaccine coverage rate reached 50% in 2012, 75% in 2013. The objective was to evaluate the PCV13 impact 2 years after implementation.
Methods. Multicenter (5 hospitals), prospective study. Hospitalized children (CH) < 60 months with confirmed Invasive Pneumococal Disease (IPD) and/or consolidated pneumonia (CP) (WHO criteria) during 5 years (prevaccine period: 2009-2011 and post-vaccine period: 2012-2013) were included. Patients (pts) with CP or empyema (E) confirmed by any other agent than S.pneumoniae were excluded. Demographic and clinical data were recorded.
Results. Pts included 1528; 1194(78%) CP, of 51/1120(4,5%) defined as Pneumococal-CP (P-CP); E:249(16.3%), 84/234(35.9%) of them confirmed as Pneumococal-E (PE) by culture; Meningitis 38(2,5%); other IPD:51(3,3%), including bacteremia, peritonitis, arthritis. The coverage rate in 2012 was 50% and 75% in 2013.
The decrease of IPD, CP and Pneumococcal Pulmonary Disease (PPD) (defined as P-CP + PE), after vaccination was: 
